Investigational drugs in clinical trials for Hidradenitis Suppurativa.
Peter Theut RiisLinnea R ThorlaciusGregor B JemecPublished in: Expert opinion on investigational drugs (2017)
Currently, MABp1, Secukinumab, CJM112, Apremilast and IFX-1 are being investigated in Phase I and II trials and offer theoretical and promising new treatment options. A trial with the drug MEDI8968 has been terminated with disappointing results. Metformin, Botulinum Toxin B, Provodine, Benzoyl Peroxide and intralesional triamcinolone are being tested as well. Treatment of Hidradenitis remains a challenge and quality RTCs are needed. Studies indicates a range of potential targets for therapy such as interleukin-1 and interleukin-17, but 'broad-spectrum' immunosuppressants like phosphodiesterase-4 inhibitors are being examined as well. A range of outcomes, including Physician Global Assessment, Sartorius scores and hidradenitis suppurativa clinical response are used in these trials, making future meta-analysis of the data difficult.
Keyphrases
- hidradenitis suppurativa
- botulinum toxin
- clinical trial
- phase ii
- phase iii
- primary care
- emergency department
- study protocol
- ankylosing spondylitis
- electronic health record
- open label
- current status
- drug induced
- randomized controlled trial
- double blind
- case control
- stem cells
- rheumatoid arthritis
- quality improvement
- metabolic syndrome
- risk assessment
- systemic lupus erythematosus
- artificial intelligence
- insulin resistance
- adverse drug
- cell therapy